<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650091</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00020066</org_study_id>
    <secondary_id>U10HL080413-03</secondary_id>
    <nct_id>NCT00650091</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF</brief_title>
  <acronym>PANTHER-IPF</acronym>
  <official_title>Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a long-term lung disease that affects an individual's
      ability to breathe. In this randomized, double-blind, placebo-controlled trial, we assigned
      patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment
      to one of three groups — receiving a combination of prednisone, azathioprine, and NAC
      (combination therapy), NAC alone, or placebo — in a 1:1:1 ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPF is a disease with widespread and permanent scarring of lung tissue which eventually
      results in death. Individuals with IPF may experience breathing difficulties, cough, chest
      pain, and a decreased exercise capacity. Although the cause of IPF is unknown, it may be a
      result of an inflammatory response to an unknown substance. NAC, an antioxidant that is
      effective at loosening up mucus that forms in the lungs, may improve lung function. The
      purpose of this study is to evaluate the effectiveness of NAC at preventing the loss of lung
      function in people with IPF.

      In the initial double-blind, placebo-controlled trial, subjects who have idiopathic pulmonary
      fibrosis with mild-to-moderate impairment in pulmonary function are randomly assigned to
      receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine
      alone; or placebo.

      After safety concerns were identified by the data and safety monitoring board, the three-drug
      regimen was stopped by the National Heart, Lung, and Blood Institute (NHLBI) on October 14,
      2011, and a clinical alert was issued. After a brief period of interruption for modification
      of the protocol and approval by the institutional review boards, patients continued to be
      recruited for the acetylcysteine group and the placebo group and were followed for the
      pre-specified duration of 60 weeks.

      Study visits will occur at baseline and Weeks 4, 15, 30, 45, and 60. At all study visits, a
      physical exam and blood collection will occur. At selected visits, the following study
      procedures will occur: lung function testing; urine collection; a 6-minute walk test, and
      questionnaires to assess health status, breathing, and quality of life. Participants will
      record medication usage and symptoms in a daily diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Change in Forced Vital Capacity</measure>
    <time_frame>Measured as the estimated change from baseline to Week 60</time_frame>
    <description>Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Measured at Week 60</time_frame>
    <description>The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression.
The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbations</measure>
    <time_frame>Measured at Week 60</time_frame>
    <description>The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions:
1. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Infections</measure>
    <time_frame>Measured at Week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maintained Forced Vital Capacity Response</measure>
    <time_frame>Measured at Week 60</time_frame>
    <description>Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 60 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine (NAC)</intervention_name>
    <description>Participants will receive 600 mg of NAC three times a day.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo each day.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Forced vital capacity (FVC) greater than or equal to 50% of predicted value

          -  Diffusion capacity (DLCO) greater than or equal to 30% of predicted value

          -  Diagnosis of IPF by modified American Thoracic Society (ATS) criteria in the 48 months
             before study entry

        Exclusion Criteria:

          -  History of clinically significant environmental exposure known to cause pulmonary
             fibrosis

          -  Diagnosis of connective tissue disease as the likely cause of the interstitial disease

          -  Extent of emphysema greater than the extent of fibrotic change (i.e., honeycombing,
             reticular changes) on high resolution computed tomography (HRCT) scan

          -  Forced expiratory volume in 1 second (FEV1)/FVC ratio less than 0.65 at the time of
             screening (post-bronchodilator)

          -  Partial pressure of arterial oxygen (PaO2) less than 55 mm Hg (less than 50 mm Hg at
             Denver study site)

          -  Residual volume greater than 120% predicted at the time of screening
             (post-bronchodilator)

          -  Evidence of active infection

          -  Significant bronchodilator response on screening spirometry, defined as change in FEV1
             greater than or equal to 12% and absolute change greater than 200 mL OR change in FVC
             greater than or equal to 12% and absolute change greater than 200 mL

          -  Screening and baseline FVC measurements (in liters, post-bronchodilator) differing by
             11%

          -  Listed for lung transplantation

          -  History of unstable or deteriorating cardiac disease

          -  Heart attack, coronary artery bypass, or angioplasty in the 6 months before study
             entry

          -  Unstable angina pectoris or congestive heart failure requiring hospitalization in the
             6 months before study entry

          -  Uncontrolled arrhythmia

          -  Severe uncontrolled high blood pressure

          -  Known HIV or hepatitis C

          -  Known cirrhosis and chronic active hepatitis

          -  Active substance and/or alcohol abuse

          -  Pregnant or breastfeeding

          -  Women of childbearing potential who are not using a medically approved means of
             contraception

          -  Any clinically relevant lab abnormalities, including the following:

               1. Creatinine greater than twice the upper limit of normal (ULN)

               2. Hematology outside of specified limits

                    1. White blood cells less than 3,500/mm3

                    2. Hematocrit less than 25% or greater than 59%

                    3. Platelets less than 100,000 mm3 at the time of screening

               3. Any of the following liver function test criteria above specified limits

                    1. Total bilirubin greater than twice the ULN

                    2. Aspartate (AST) or alanine aminotransferases (ALT) greater than 1.5 the ULN

                    3. Alkaline phosphatase greater than three times the ULN

                    4. Albumin less than 3.0 mg/dL at the time of screening

          -  Known hypersensitivity to study medication

          -  Any condition other than IPF that, in the opinion of the site PI, is likely to result
             in death in the 1 year after study entry

          -  Any condition that, in the judgment of the PI, might cause participation in this study
             to be detrimental or makes the person a poor candidate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marvin I Schwarz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rob Kaner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College at Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Talmadge King, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joe Lasky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Loyd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernando Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Imre Noth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ganesh Raghu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesse Roman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Belperio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Anstrom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gail Weinmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Chapman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lake Morrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kallay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Highland Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Sahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Glassberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Milton Rossman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Fitzgerald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Beth Scholand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Ettinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Antin-Ozerkis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joao deAndrade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Rosas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Zibrak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Isreal-Deaconess</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Padilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital - University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Universtiy</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/databases/alerts/2011_nhlbi_ifp.html</url>
    <description>Clinical Alert: Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <results_first_submitted>July 31, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2015</results_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Azathioprine</keyword>
  <keyword>NAC</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Initial Study Design: Subjects are randomly assigned to receive a three-drug regimen of prednisone, azathioprine, and acetylcysteine; acetylcysteine alone; or placebo.
Amended Study Design: The three-drug regimen was removed from the protocol due to safety concerns on 10/14/2011. Subjects are randomly assigned to acetylcysteine or placebo.</recruitment_details>
      <pre_assignment_details>Participants in the Pred/AZA/NAC group were discontinued and not re-randomized in the amended study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N-Acetylcysteine</title>
          <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
        </group>
        <group group_id="P3">
          <title>Pred/AZA/NAC</title>
          <description>The prednisone dose was started at 0.5 mg per kilo- gram of ideal body weight and was tapered to 0.15 mg per kilogram during a period of 25 weeks.
The azathioprine dose (maximum, 150 mg per day) was based on the patient’s ideal weight, concurrent use of allopurinol, and thiopurine methyl-transferase (TPMT) activity. NAC was prescribed at 600 mg orally three times a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Study Design - Interim Analysis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Amended Study Design</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="0">Study Drug was discontinued for all subjects due to safety concerns.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lung transplantation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-Acetylcysteine</title>
          <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="131"/>
            <count group_id="B3" value="264"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="6.4"/>
                    <measurement group_id="B2" value="67.2" spread="8.2"/>
                    <measurement group_id="B3" value="67.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Change in Forced Vital Capacity</title>
        <description>Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters)</description>
        <time_frame>Measured as the estimated change from baseline to Week 60</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Change in Forced Vital Capacity</title>
          <description>Change from Baseline in Forced Vital Capacity at 60 weeks (units in liters)</description>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-0.23" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-0.24" upper_limit="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression</title>
        <description>The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression.
The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline.</description>
        <time_frame>Measured at Week 60</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression</title>
          <description>The time-to-death or a 10% decline in FVC will be defined as the time-to-disease progression.
The 10% decline in FVC from enrollment must be confirmed on 2 consecutive visits no less than 6 weeks apart. For subjects with 2 consecutive visits with a 10% decline in FVC, the time-to-disease progression will be defined as the time interval between enrollment and the initial visit with a 10% FVC decline.</description>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="20.1" upper_limit="36.0"/>
                    <measurement group_id="O2" value="26.5" lower_limit="19.5" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Exacerbations</title>
        <description>The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions:
1. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax.</description>
        <time_frame>Measured at Week 60</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Exacerbations</title>
          <description>The following 3 criteria will define acute exacerbations in subjects with acute worsening of their respiratory conditions:
1. Clinical (all of the following required): A) Unexplained worsening of dyspnea or cough within 30 days, triggering unscheduled medical care (e.g., emergency room, clinic, study visit, hospitalization). B) No clinical suspicion or overt evidence of cardiac event, pulmonary embolism, or deep venous thrombosis to explain acute worsening of dyspnea. C) No pneumothorax.</description>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiratory Infections</title>
        <time_frame>Measured at Week 60</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Infections</title>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maintained Forced Vital Capacity Response</title>
        <description>Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline.</description>
        <time_frame>Measured at Week 60</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maintained Forced Vital Capacity Response</title>
          <description>Maintained forced vital capacity response was a binary variable taking on a value of 1 for participants with higher FVC % predicted at week 60 compared to baseline.</description>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Change in Forced Vital Capacity</title>
        <description>Change from Baseline in Forced Vital Capacity at 15, 30, 45, and 60 weeks (units in liters)</description>
        <time_frame>Baseline, 15, 30, 45, 60 week</time_frame>
        <population>Analysis population includes participants from the amended study design only.</population>
        <group_list>
          <group group_id="O1">
            <title>N-Acetylcysteine</title>
            <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity</title>
          <description>Change from Baseline in Forced Vital Capacity at 15, 30, 45, and 60 weeks (units in liters)</description>
          <population>Analysis population includes participants from the amended study design only.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.19"/>
                    <measurement group_id="O2" value="-0.04" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.20"/>
                    <measurement group_id="O2" value="-0.08" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.25"/>
                    <measurement group_id="O2" value="-0.15" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.26"/>
                    <measurement group_id="O2" value="-0.15" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are reported for amended study only.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-Acetylcysteine</title>
          <description>Participants will receive N-acetylcysteine (NAC) for 60 weeks.
N-acetylcysteine (NAC): Participants will receive 600 mg of NAC three times a day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 60 weeks.
Placebo: Participants will receive placebo each day.</description>
        </group>
        <group group_id="E3">
          <title>Initial Study: Pred/AZA/NAC</title>
          <description>Participants will receive prednisone, azathioprine, and N-acetylcysteine (NAC) for 60 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Initial Study: Placebo</title>
          <description>Placebo: Participants will receive placebo each day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Acute Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Drug Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Drug Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Intersticial Lung Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Exacerbation of Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="133"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="133"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="133"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="131"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="133"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="133"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="131"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="133"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="131"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kevin J Anstrom</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919-668-8902</phone>
      <email>kevin.anstrom@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

